Recent Advances in Biopharmaceutical and Precision Medicine Platforms

Share this:
Published: 22 Sep 2017

This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across biopharmaceutical and precision medicine platforms. A summary of key clinical trials for Patidegib and Quizartinib therapies is also depicted, along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Biopharmaceuticals, precision medicine, genetic disorders, leukemia, enhanced delivery platform, genomics


Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..